No Data
No Data
Form 144 | Arrowhead Pharmaceuticals(ARWR.US) Officer Proposes to Sell 237.41K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 2, $Arrowhead Pharmaceuticals(ARWR.US)$ Officer Oliver Tracie intends to sell 9,394 shares of its common stock on Jul 2, with a total market value of approximately $237.41K
The Past Three Years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Investors Has Not Been Profitable
TD Cowen Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating
TD Cowen analyst Brendan Smith maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.5% and a total average return of -3.2%
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Express News | Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Citi Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29
Citi analyst David Lebovitz maintains $Arrowhead Pharmaceuticals(ARWR.US)$ with a hold rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 51.4%